| MISUSED & MISUNDERSTOOD | | Posted Thursday, January 11, 2007 3:12:54 PM by Blog57 Team | | So if Retin-A is so effective and so well studied, why isn't everyone using it? Many dermatologists blame a lack of patient education. "It's one of the most misunderstood drugs," said Dr. Kenneth Beer, a dermatologist in Palm Beach, Fla., and a clinical investigator for Allergan, the maker of prescription Avage and Tazorac. He is an Allergan shareholder. People use Retin-A too much, use it too often, experience negative side effects and give up on it too soon, doctors say. The problem with Retin-A is that it may actually make skin look worse — with redness, flakiness and peeling — for up to eight weeks. "But by 24 weeks, patients will see dramatic, marked improvements," said Dr. Min-Wei Christine Lee, a dermatologist in Walnut Creek, Calif.. Florida firefighter Susan Hobbs said when she first started using Retin-A, she broke out with severe acne.... | |
| |
| | | CollaGenex Pharmaceuticals Signs License and Supply Agreement with ... | | Posted Monday, January 01, 2007 1:13:51 PM by Blog57 Team | | Announced that it has signed a License and Supply Agreement with MediGene AG for marketing rights to Oracea(TM), CollaGenex's flagship dermatology product for the systemic treatment of rosacea, in the European Union, certain contiguous countries and Russia. NEWTOWN, PA, USA | Dec 20, 2006 | CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it has signed a License and Supply Agreement with MediGene AG for marketing rights to Oracea(TM), CollaGenex's flagship dermatology product for the systemic treatment of rosacea, in the European Union, certain contiguous countries and Russia. MediGene is a German biopharmaceutical company that is developing novel pharmaceuticals for the treatment of dermatology, cancer and certain autoimmune conditions.Under the License and Supply Agreement, MediGene receives the right to manufacture, register, market and sell Oracea in the European Union, certain contiguous countries and Russia.... | |
| |
| | | Business of beauty | | Posted Sunday, November 12, 2006 11:17:43 PM by Blog57 Team | | Nestled in among a mostly empty portion of downtown Opelousas is a company that has just expanded its services. Bella M, located on 109 S. Main St., has been open for two years and offers a selection of clothes that would be found in stores in large cities. Before, it only sold trendy clothes one would find in metro areas, but the store now offers customers a chance to receive massages, facials, skin treatments and other relaxation and beautification services. .... | |
| |
| | | DUSA Pharmaceuticals to Present at CIBC World Markets 17th Annual Healthcare Conference | | Posted Wednesday, November 08, 2006 11:19:15 PM by Blog57 Team | | DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), today announced that Dr. Geoff Shulman, Chairman and CEO and Mr. Bob Doman, President and COO, will present a corporate overview at the CIBC World Markets 17th Annual Healthcare Conference on Monday, November 6, 2006 at 4:25 p.m. ET at The Waldorf-Astoria Hotel in New York. Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 14 days following the presentation. About DUSA Pharmaceuticals DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products.... | |
| |
| | | Researchers Have New Way To Treat Liver Tumors | | Posted Thursday, November 02, 2006 1:38:37 PM by Blog57 Team | | CARY, N.C. -- In the United States, more than 100,000 people die each year from liver tumors. It is the place where lung, colon and breast cancers eventually metastasize or spread. It is also a difficult cancer to treat with traditional chemotherapy and radiation. For several years, Letha House kept going to the doctor with fatigue and diarrhea. "They kept telling me I had irritable bowel syndrome. (I) was treated for that. (I) was treated for rosacea because I had the permanent flush on my face," House said. Those are also the symptoms for carcinoid syndrome. Carcinoid tumors usually begin in the colon and spread to the liver or other organs. A CT scan showed that had happened to House. "I guess the tumors in my liver just lit up when they did that," he said.... | |
| |
| | | Ground Zero Pharmaceuticals Announces Expansion of Regulatory Consulting Services to International Clinical Trial | | Posted Wednesday, November 01, 2006 11:37:06 PM by Blog57 Team | | IRVINE, Calif., Nov. 1 /PRNewswire/ -- The landscape of new drugs, biologicals and combinations with medical devices has been dramatically changed by increased costs and safety concerns raised by physicians and regulatory agencies. More organized, effective and proactive medical product programs lead to fewer failed products while expediting FDA approval. Ground Zero Pharmaceuticals, Inc. (GZP), a regulatory affairs and product development consulting company, has added additional expertise in clinical protocol development, study auditing and pharmacogenomics. Working seamlessly with clinicians and data management partners, the firm provides sophisticated regulatory and medical strategy, preclinical study planning and review, biostatistical analysis, medical writing, manufacturing compliance, and clinical trials conduct for programs in the US, Australasia, and Europe.... | |
| |
| | | Mint craving might signal missing mineral | | Posted Tuesday, October 24, 2006 11:15:23 PM by Blog57 Team | | Ihad a gastric bypass 32 months ago. Last year, I started craving mint in everything: mint coffee, ice cream, cake, cookies, even mint lip balm. It has now gotten worse. I am worried, because all I want to do is sit down with a tube of mint ChapStick and eat my heart out. I have asked other bypass people if they crave nonfood items. Some have said they eat lip balm for the waxiness. I told a doctor, but he laughed it off and said mint would not hurt me. Why am I craving mint? I just found out I do have a very low iron level. Could this be the problem? Your very low iron level could indeed be contributing to your craving. Iron or zinc deficiency is sometimes associated with a condition called pica. This is the medical term for craving and eating nonfood substances.... | |
| |
| | | Correction: Oct. 17 Dusa Brazil Story | | Posted Saturday, October 21, 2006 11:12:56 AM by Blog57 Team | | In an Oct. 17 story about the Brazilian government's approval of Dusa Pharmaceuticals Inc.'s Levulan Kerastick, The Associated Press described the solution as an acne drug. While the solution is being developed as a treatment for acne, the company received Brazilian approval specifically for use in treating pre-cancerous actinic keratoses. A corrected version of the story appears below. WILMINGTON, Mass. (AP) -- Dusa Pharmaceuticals Inc., which makes treatments for acne and rosacea, said Tuesday that Stiefel Laboratories Inc., its marketing partner for Latin America, received Brazilian regulatory approval for one of its drugs for use in treating pre-cancerous actinic keratoses. The announcement sent Dusa shares up 16 cents, or 3.7 percent, to $4.45 in morning trading on the Nasdaq.... | |
| |
| | | Dusa Gets Brazilian OK for Acne Solution | | Posted Wednesday, October 18, 2006 3:18:54 AM by Blog57 Team | | Dusa Pharmaceuticals Inc., which makes treatments for acne and rosacea, said Tuesday that Stiefel Laboratories Inc., its marketing partner for Latin America, has received Brazilian regulatory approval for one of its acne drugs. The announcement sent Dusa shares up 16 cents, or 3.7 percent, to $4.45 in morning trading on the Nasdaq. Over the past year, Dusa shares have traded between $3.52 and $11.12. Dusa officials said additional launches of the drug are expected to follow in a number of other Latin American countries, subject to regulatory approvals. Levulan Kerastick is a solution to prime the skin, making affected areas more sensitive to light treatment. .... | |
| |
| | | CollaGenex borrows more to finance drug launch | | Posted Saturday, October 14, 2006 3:09:35 PM by Blog57 Team | | CollaGenex Pharmaceuticals Inc. signed a loan modification agreement Wednesday with SVB Silicon Valley Bank to expand the company's line of credit from $5 million to $10 million. The expanded credit facility will have a term of two years, with no principal repayments required before the end of the term. Officials at the Newtown, Pa., biopharmaceutical company said the line of credit will be available to fund the company's working capital needs. Nancy C. Broadbent, chief financial officer of CollaGenex (NASDAQ:CGPI - News), said the deal will enhance the company's "financial flexibility" to fund costs associated with its launch of Oracea, a treatment for rosacea approved by the Food and Drug Administration in May. CollaGenex launched Oracea in July. SVB Silicon Valley Bank is a subsidiary of SVB Financial Group (NYSE:SIVB - News) of Santa Clara, Calif.... | |
| |
| |
|
|
